Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to produce its own GLP-1 hormone naturally.

New research reveals these medications impact everything from heart health to restaurant menus.

Diabetes care is undergoing a major transformation driven by GLP-1 receptor agonists, which have expanded beyond glycemic ...

USA: Therapy with glucagon-like peptide-1 receptor agonists (GLP-1RAs) after heart transplantation was associated with ...

Series D1 financing with participation from a syndicate of global healthcare-focused investors, including RTW Investments, SR One Capital ...

A new study reveals stopping GLP-1 weight loss drugs leads to rapid weight regain, nearly four times faster than quitting ...

New weight-loss drugs in the works will offer more choices beyond GLP-1 options Wegovy and Zepbound. What to know about ...

Corxel Pharmaceuticals Ltd. completed a $287 million series D round to advance its lead compound, an oral small-molecule GLP-1 receptor agonist, CX-11, for obese and overweight patients. Headquartered ...

The landscape of weight management has evolved dramatically in recent years, with GLP-1 receptor agonists like Semaglutide leading the way in treating obesity. However, a new contender has emerged: ...

A new study published in Otolaryngology–Head and Neck Surgery reveals that glucagon-like peptide-1 receptor agonists ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease in the Western world, driven by obesity, insulin resistance, and systemic inflammation.

Three global experts in endocrinology and diabetes on Monday shared new insights and the latest research on treatment options ...